PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) announced the recent appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board, effective December 4, 2023. A proven leader with over 20 years of global experience across the healthcare industry, Dr. Pfeiffenberger most recently served as Chief Operating Officer at Neogene Therapeutics, a wholly owned subsidiary of AstraZeneca focused on developing cell therapies for the treatment of cancer. In connection with the appointment, Greg Russotti, Ph.D., who has served as Century’s Interim Chief Executive Officer since April 2023, will assume the role of Chief Technology and Manufacturing Officer, an expanded role from his previous position as Chief Technology Officer.
“Brent is a strong leader with extensive experience across the research, development, and commercialization of lifesaving drugs. His unique strategic leadership and operational acumen will serve Century well, and we are thrilled to have him join as Chief Executive Officer,” said Joe Jimenez, Chairman of the Board. “On behalf of the entire Board, I would like to thank Greg Russotti for his exceptional leadership and unwavering dedication during the interim period. We look forward to his continued contributions in the newly created role of Chief Technology and Manufacturing Officer, as Century looks to leverage its manufacturing expertise and state-of-the-art GMP manufacturing facility to generate additional value.”
“Century is a pioneer on the cutting-edge of the allogeneic cell therapy space, and with its first clinical data readout expected by year-end, it is an honor to join as Chief Executive Officer at this exciting time,” said Dr. Pfeiffenberger. “Leveraging the proprietary Allo-Evasion™ platform, the Company is uniquely positioned to develop differentiated allogeneic cell therapies and expand patient access to life-saving medicines. I look forward to working alongside Greg and the talented Century team to continue to advance the Company’s innovative pipeline and serve patients in need.”
As Chief Operating Officer of Neogene Therapeutics, Dr. Pfeiffenberger played a central role in driving Neogene’s evolution from a preclinical company to a global, clinical-stage organization with multiple assets, ultimately culminating in its acquisition by AstraZeneca earlier this year. Prior to Neogene, Dr. Pfeiffenberger spent nearly two decades in leadership roles of increasing responsibility at Bristol Myers Squibb, most recently as Senior Vice President, Head of U.S. Oncology, where he oversaw business operations for the multi-billion dollar franchise. Prior to this role, he held several critical global leadership positions where he built, led, and expanded commercial and business operations, including as Co-Lead, Head of Worldwide Commercial Oncology, where he closely partnered with the Research and Development team on the creation and delivery of global development strategies for a large-scale oncology program. He began his career at Bristol Myers Squibb serving in several roles across a broad range of functions and therapeutic areas, including marketing, sales, market access and pricing, business development, and strategy and operations. Dr. Pfeiffenberger received his Pharm.D. from Duquesne University and his MBA from the Wharton School of Business at the University of Pennsylvania.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.